Heart failure & cardiomyopathiesCohort study
Cardiac Biomarker Complete Response in AL Amyloidosis
- Retrospective cohort study
- single-centre
Authors' conclusion
Cardiac biomarker CR represents the deepest level of cardiac biochemical recovery in AL amyloidosis and is associated with survival similar to the general population.
Study context
- Population
- Patients with AL cardiac amyloidosis diagnosed 2004–2023 eligible for cardiac biomarker response (baseline NT-proBNP >650 pg/mL or BNP >150 pg/mL)63 achieved cardiac biomarker complete response (CR)
- Participants
- 1,342 patients
- Outcome
- Cardiac biomarker CR (NT-proBNP ≤350 pg/mL or BNP ≤80 pg/mL sustained ≥12 months): presentation, treatment, cardiac recovery and survival
- Follow-up
- Median 9.5 years
Main finding
As reported in the abstract
Cardiac biomarker CR
Cardiac biomarker CR achieved (63 of 1,342 evaluable)
4.7%
Survival of CR patients vs matched general US population: comparable
P = 0.35
Deaths among CR patients (2 of non-AL cardiac amyloidosis (CA)-related causes)
8
Observational data: associations, not effects.
Further findings
Cardiac biomarker CR by period
P < 0.001
- Cardiac biomarker CR by period: denominators 591 vs 751
Characteristics and course of CR patients
- Median time to cardiac biomarker CR
- 20.6 months
- Median NT-proBNP at CR
- 265 pg/mL
- NT-proBNP reduction from baseline at CR
- 86.9%
- Median pretreatment NT-proBNP
- 1,977 pg/mL
- Hematologic CR preceded cardiac biomarker CR
- 76%
- Cardiac progression
- 14%
- Required subsequent clone-directed therapy
- 44.4%
- Echocardiographic parameters improved but did not fully normalize in all patients
Original publication
Cardiac Biomarker Complete Response in AL Amyloidosis. JACC CardioOncol. doi:10.1016/j.jaccao.2026.01.004
Summarised from the published abstract; every number is checked against it